Suppr超能文献

使用分次全身淋巴照射诱导成年小鼠特异性组织移植耐受:同种异体骨髓和皮肤移植的长期存活

Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts.

作者信息

Slavin S, Strober S, Fuks Z, Kaplan H S

出版信息

J Exp Med. 1977 Jul 1;146(1):34-48. doi: 10.1084/jem.146.1.34.

Abstract

BALB/c mice were treated with fractionated high dose (3,400 rads) total lymphoid irradiation (TLI), and given semiallogeneic (BALB/c x C57BL/Ka) or allogeneic (C57BL/Ka) bone marrow and/or skin allografts. TLI alone prolonged the mean survival time (m.s.t.) of C57BL/Ka skin grafts to 49.1 days (control, 10.7 days). Shielding of the thymus during TLI produced only a slight increase in graft survival (m.s.t., 19 days). TLI combined with splenectomy was no more effective than TLI alone. Infusion of 10(7) semiallogeneic or allogeneic bone marrow cells after TLI produced stable chimeras in 7/8 and 8/15 recipients, respectively. Chimeras were specifically tolerant to donor tissues, since C57BL/Ka skin grafts were accepted for more than 250 days, but third-party (C3H/He) skin grafts were rejected rapidly. In addition, chimeric lymphocytes responded to C3H/He and C3H. Q but not to C57BL/Ka cells in the one-way mixed leukocyte reactions. BALB/c C57BL/Ka chimeras showed no clinical evidence of graft vs. host disease. These findings may have application of clinical organ transplantation, since (a) the recipient treatment (TLI) has already been shown to be safe in humans, (b) donors and recipients can be completely allogeneic, and (c) bone marrow and skin graft survival was permanent (greater than 250 days).

摘要

用分次大剂量(3400拉德)的全身淋巴照射(TLI)处理BALB/c小鼠,并给予半同种异体(BALB/c×C57BL/Ka)或同种异体(C57BL/Ka)骨髓和/或皮肤同种异体移植。单独的TLI将C57BL/Ka皮肤移植的平均存活时间(m.s.t.)延长至49.1天(对照组为10.7天)。TLI期间对胸腺进行屏蔽仅使移植存活略有增加(m.s.t.,19天)。TLI联合脾切除术并不比单独的TLI更有效。TLI后输注10⁷个半同种异体或同种异体骨髓细胞分别在7/8和8/15的受体中产生了稳定的嵌合体。嵌合体对供体组织具有特异性耐受性,因为C57BL/Ka皮肤移植被接受超过250天,但第三方(C3H/He)皮肤移植被迅速排斥。此外,在单向混合淋巴细胞反应中,嵌合淋巴细胞对C3H/He和C3H.Q有反应,但对C57BL/Ka细胞无反应。BALB/c C57BL/Ka嵌合体没有移植物抗宿主病的临床证据。这些发现可能适用于临床器官移植,因为(a)受体治疗(TLI)已被证明对人类是安全的,(b)供体和受体可以完全是同种异体的,并且(c)骨髓和皮肤移植存活是永久性的(超过250天)。

相似文献

引用本文的文献

本文引用的文献

3
Actively acquired tolerance of foreign cells.对外源细胞的主动获得性耐受。
Nature. 1953 Oct 3;172(4379):603-6. doi: 10.1038/172603a0.
4
Mouse thymic iso-antigens.小鼠胸腺同种抗原。
Nature. 1966 Jan 29;209(5022):521-3. doi: 10.1038/209521b0.
6
Modification of renal homograft rejection by irradiation.辐射对同种肾移植排斥反应的影响
Transplantation. 1967 Jul;5(4):Suppl:1174-91. doi: 10.1097/00007890-196707001-00055.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验